Details of Disease

General Information of Disease (ID: DIS88DJO)

• Disease Name: Exudative age-related macular degeneration
• Disease Class: 9B71: Retinopathy
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS88DJO: Exudative age-related macular degeneration
• ICD Code:
  ICD-11: ICD-11: 9B78.3Z
  ICD-9: ICD-9: 362.5
  Expand ICD-11: '9B78.3Z
  Expand ICD-9: 362.5
• Disease Identifiers:
  MedGen ID: 543162
  SNOMED CT ID: 414173003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aflibercept	DMT3D5I	Approved	NA	[1]
Ranibizumab	DMSYPNW	Approved	Antibody	[2]
Verteporfin	DMIY6DB	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AdPEDR	DME384W	Phase 2	Small molecular drug	[4]
Sirna-027	DMZTQD8	Phase 1/2	siRNA drug	[5]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevasiranib	DMIEB8Y	Discontinued in Phase 3	siRNA drug	[6]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187.
• [2] Age-related macular degeneration: anti-vascular endothelial growth factor treatment. BMJ Clin Evid. 2016 Feb 24;2016:0701.
• [3] Verteporfin FDA Label
• [4] Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35.
• [5] 2011 Pipeline of Sirna Therapeutics.
• [6] 2011 Pipeline of Acuity Pharmaceuticals.